Loading clinical trials...
Loading clinical trials...
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alto Neuroscience
NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression
NCT06843187 · Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder
NCT06564818 · Major Depressive Disorder
NCT06110897 · Major Depressive Disorder
NCT04751331 · Major Depressive Disorder
Site 4058
Tucson, Arizona
Site 4082
Oceanside, California
Site 4023
Torrance, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions